Browse company news, exhibition updates, and industry insight as three distinct editorial streams.
Choose a content categoryCompany News
Company developments are kept separate from exhibition reporting and industry analysis so each publication has a clear purpose and evidence boundary.
Browse company news
Exhibitions & Events
Find current dates, venues, booth details, industry context, and the project questions worth preparing before a meeting.
Browse all exhibitions
Exhibition archive
Event pages retain the organizer source, company participation record, product-status boundary, and a qualified next step.
CPHI & PMEC Shenzhen brings ingredients, biotechnology, manufacturing, quality and market-access teams into one professional setting. At Hall 9 Booth 9G75, LUMIRABIO will focus on the evidence and project boundaries required to turn a peptide name into a reviewable B2B API requirement.
At CPHI China 2026, LUMIRABIO discussed semaglutide-, tirzepatide- and retatrutide-related peptide programs with pharmaceutical, CMC, procurement and development teams. The most useful conversations moved quickly from product names to specifications, impurity profiles, batch evidence and market-specific feasibility.
LUMIRABIO joined the sixth China (Xiamen) International Cross-Border E-Commerce Exhibition to meet platforms, buyers and supply-chain partners and to present its peptide raw-material portfolio and technical platform to a broader international business audience.
At the 94th API China in Shanghai, LUMIRABIO presented peptide raw-material and formulation-development topics and met distributors, pharmaceutical companies and research teams. This recap connects those conversations to the evidence qualified buyers need after an exhibition.
Longer-form analysis on peptide science, development, CMC, analytical control, quality evidence, and qualified sourcing decisions.
A CoA is necessary, but not sufficient. A defensible Retatrutide material review connects the exact supplied form, actual manufacturer and site, batch genealogy, analytical purpose and destination-market boundary before commercial discussion.
A familiar molecule name and a polished CoA are not enough if the manufacturing site, batch history, analytical controls, and U.S. import roles cannot be reconciled. FDA Import Alert 66-80 gives GLP-1 API buyers a practical framework for asking those questions before shipment.
From the FDA's review of selected compounding substances to pivotal multi-agonist programs, amylin combinations and AI-assisted design, these six signals show how peptide innovation is reshaping development strategy while raising the bar for CMC evidence.
Modern metabolic drug programs increasingly build on peptide hormones such as GLP-1, GIP and amylin. The reason lies in receptor biology, while successful products also depend on half-life engineering, delivery technology and rigorous CMC control.
Endogenous peptides form a diverse communication network across endocrine, neural, metabolic and immune pathways. Understanding how those signals are produced, received and cleared gives peptide discovery and CMC teams a more useful starting point than treating peptides as a single therapeutic class.
Industry & Technical Insights · Technical briefs
Short decision frameworks for impurity control, process scale-up, and productive peptide API meetings. Existing bilingual resources remain available.
Review material balance, purification, isolation, analytics, equipment assumptions, and transfer readiness as one operating context.
Read the technical brief
Connect process risks, orthogonal analytical methods, specifications, and method-transfer readiness in one review.
Read the analytical brief
Bring a clear molecule, specification, quantity, market, document, destination, and timing brief to each exhibition meeting.
View the meeting checklist